Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016
This report takes a look at the pipeline of the following companies. The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:
- Abbott Laboratories
- Baxter International
- Biogen IDEC
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene Corp.
- Daiichi Sankyo
- Dainippon Sumitomo
- Eli Lilly & Co.
- Gilead Sciences
- Grifols SA
- Johnson & Johnson
- Kyowa Kirin
- Merck KGaA
- Mitsubishi Tanabe Pharma
- Novo Nordisk
- Ono Pharmaceutical Co.
- Otsuka Pharmaceutical
- Purdue Pharma
- Reckitt Benckiser
- Santen Pharmaceuticals
- Taisho Pharmacueitcal
- Valeant Pharmaceuticals
- Warner Chilcott
This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.As part of its coverage, the report provides the following:
- Company Analysis
- Pipeline Snapshot: Top 20 Companies
- Market Trends and Value
- Evaluating Changes in 2011 Market Value
- The Traditional Pharmaceutical Market
- Biotechnology Market Facts and Forecast
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.
The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders. Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.
Issues and Trends discussed in this report include:
- Biotechnology Drug Development
- Orphan Drugs
- Fast Track Drug Status
- Other Accelerated Methods for Drug Approval
- Pharmaceutical Regulatory Exclusivity
- Biosimilar Development
- Aging Populations
- Mergers, Acquisitions, and Collaborations
- Contributors to R&D Success
- R&D Spending Trends
- The Role of Contract Research Organizations
- Sustainability in a Changing Pharmaceutical Industry
Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).
Please note that your term must be at least three characters long and numbers will be blocked by the # sign.